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  EVIDENCE-BASED ANSWER 
Tricyclic antidepressants, anticonvulsants, and capsaicin reduce the pain of diabetic neuropathy; limited data 
suggests that lidocaine patches may also be efficacious. Both tricyclic antidepressants and anticonvulsants are 
superior to placebo in relieving painful diabetic neuropathy. Compared with placebo, patients taking tricyclic 
antidepressants report reduced pain (number needed to treat [NNT] for at least 50% reduction= 3.5) (strength 
of recommendation [SOR]: A). Similarly, patients taking anticonvulsants report reduced pain (NNT for at least 
50% reduction in pain=2.7) (SOR: A). 
Limited evidence suggests that selective serotonin reuptake inhibitors (SSRIs) are no more efficacious than 
placebo (SOR: C). Both anti-depressants and anticonvulsants have a high rate of minor adverse effects 
(number needed to harm [NNH]=2.7 for both). Tricyclic antidepressants have an NNH of 17 for side effects 
severe enough that patients withdrew from the study. 
Compared with placebo, topical capsaicin also reduces pain (NNT=4) (SOR: A); however, there are no 
systematically collected data on side effects for capsaicin. A single case series demonstrates that lidocaine 
patches are efficacious for neuropathic pain, though expensive (SOR: B). Almost no trials comparing different 
classes of treatments have been performed. 
  EVIDENCE SUMMARY 
A recent well-done meta-analysis1 summarized available randomized placebo-controlled trials of 
antidepressants (including tricyclics and SSRIs) and anticonvulsants (including phenytoin, carbamazepine, and 
gabapentin). Almost all trials compare individual agents against placebo, and there have been no head-to-head 
trials that address functional outcomes, quality of life, patient satisfaction, or cost. Most trials do not describe 
diagnostic criteria, consider causes of pain other than diabetes or address diabetic control, which is known to 
predict frequency of neuropathy. Finally, very few trials include typical primary care patients in a primary care 
setting or control for important confounding variables such as over-the-counter medications or comorbid 
illnesses. 
Within the constraints of this literature, place-bos have a substantial impact, with an aggregate 32% of patients 
receiving placebo reporting at least 50% reduction in pain. A total of 16 trials have addressed the efficacy of 
antidepressants for diabetic neuropathy. Compared with placebo, tricyclic antidepressants have an aggregate 
NNT of 3.5 (95% confidence interval [CI], 2.6–4.7) for patients reporting at least 50% reduction of pain, along 
with an NNH of 2.7 (95% CI, 2.1–3.9) for minor adverse effects (typically the muscarinic effects of dry mouth, 
constipation, and blurred vision) and 17 (95% CI, 10–43) for side effects severe enough to cause withdrawal 
from a trial. Dosages were in the low to middle range of those used to treat depression; there was no 
significant difference in efficacy between trials less than 3 weeks and those greater than 3 weeks. No evidence 
supports differences among different tricyclic agents, and limited evidence suggests that SSRIs are no more 
efficacious than placebo. 
A total of 4 randomized placebo-controlled trials (1 each for phenytoin [Dilantin], carbamazepine [Tegretol], 
gabapentin [Neurontin], and valproate [Depakote]) have extractable data about the efficacy of anticonvulsants 
for the pain of diabetic neuropathy. As a class, the NNT for patients reporting at least a 50% reduction in pain 
was 2.7 (95% CI, 2.2–3.8); the NNH for minor adverse effects (typically transient central nervous system effect 
such as dizziness, somnolence, or disturbance in gait) was 2.7 (95% CI, 2.2–3.4). 
These summary estimates do not include the valproate trial,2 which was reported after the meta-analysis was 
completed; the report did not allow calculation of NNT, but the findings were consistent with these results. 
Phenytoin dosage was 300 mg/d; carbamazepine dosage was titrated to 200–600 mg/d, gabapentin from 300–
3600 mg/d, and valproate 1200 mg/d. Patients taking anticonvulsants did not have a higher rate of withdrawal 
compared to those taking placebo. Limited evidence suggests no significant differences among 
anticonvulsants; there is insufficient evidence to determine optimal dosage of any of these agents. 
Studies involving topical agents are also limited. According to an information summary,3 a total of 4 trials have 
addressed the efficacy of topical capsaicin for neuropathic pain. Compared with placebo, capsaicin reduces 
pain (NNT=4; 95% CI, 2.9–6.7), but no pooled information is available on side effects or rate of study 
withdrawal. Finally, 1 case series has suggested that lidocaine patches are efficacious for diabetic 
neuropathy.4 
A variety of other interventions have been reported for diabetic neuropathy, including non-steroidal anti-
inflammatory drugs, transcutaneous electrical nerve stimulation (TENS), angiotensin-converting enzyme 
inhibitors, and Tramadol, but there have been no published systematic evaluations of them. 
The Table characterizes the agents, the number of trials that address each, the NNT, NNH, typical effective 
dose, and approximate retail cost per month with the average effective dose. 
 
TABLE 
Efficacy of drug treatments for diabetic neuropathy 
Drug Number NNT (95% NNH Efficacious Typical 
of 
controlled 
trials 
CI) for 
50% pain 
reduction 
(95% CI) dose cost 
Antidepressants 16 
3.4 (2.6–
4.7) 
2.7 (2.1–
3.9) 
      
Tricyclics 8 
3.5 (2.5–
5.6) 
3.2 (2.3–
5.2) 
Amitryptiline 
50–100 
mg/d; 
Nortryptiline 
50–75 mg/d 
$12 
SSRIs 3 
Not 
efficacious 
  N/A N/A 
Anticonvulsants* 3 
2.7 (2.2–
3.8) 
2.7 (2.2–
3.4) 
      
Phenytoin 1 
Not 
available 
3.2 (2.1–
6.3) 
300 mg/d $18 
Carbamezapine 1 
Not 
available 
Not 
available 
400 mg 2x 
daily 
$28 
Gabapentin 2 
Not 
available 
2.6 (2.1–
3.3) 
600–900 
mg 3x daily 
$333 
Valproate† 1 
Not 
available 
Rare 
400 mg 3x 
daily 
$36 
Topical 
capsaicin 
4 
4 (2.9–
6.7) 
Not 
available 
0.075% 4x 
daily 
$39 
Lidocaine patch 0 
Not 
available 
Not 
available 
1 patch 
each foot, 
daily 
$272 
Costs based on 30 days of typical efficacious dose. Retail prices from www.drugstore.com, December 2003, 
except for capsaicin, which was obtained from Walmart. 
*This summary does not include results from Kochar et al.  
†Data from this trial cannot be summarized within this framework; however, results were statistically 
significant and similar in magnitude to other trials. 
NNT, number needed to treat; NNH, number needed to harm; CI, confidence interval 
  RECOMMENDATIONS FROM OTHERS 
American Diabetes Association practice guidelines do not address neuropathy; UptoDate emphasizes 
prevention through glycemic control, with initial treatment using amitriptyline or nortriptyline, followed by 
capsaicin and anticonvulsants.5 
CLINICAL COMMENTARY: 
Anticonvulsants and antidepressants effective at 
reducing perception of pain 
 
Charissa  Fotinos,  MD 
Seattle–King County Public Health, Seattle, Wash 
The management of patients with chronic pain requires a combination of artistry and skill. As each 
individual’s perceptions, expectations and response to therapy differ, dynamic treatment 
approaches are required. The relative dearth of evidence supporting effective treatments for chronic 
pain compounds the problem. This evidence review helps to lessen some of the guesswork for 
patients with diabetic neuropathy. Anticonvulsants and antidepressants are impressively effective at 
reducing patients’ perceptions of pain at a favorable benefit to significant harm ratio, NNT of 2–4 vs. 
NNH of 18. Several things however, aren’t clear from the literature: as these were all placebo 
comparisons, which drug is more effective? As well, were reductions in functional limitation and 
disability measures or improvements in quality of life scores demonstrated? Will other newer agents 
prove to be superior? Despite these unanswered questions, for patients with diabetic neuropathy 
good evidence now supports what has likely been many clinicians’ preference for the treatment of 
most chronic pain conditions; any alternative to narcotics. 
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